Quarterly report · Q3
8086.TEDINET S100Q5DE
Period2022-04-01 → 2022-12-31
Filed2023-02-14
StandardJapan GAAP
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 36
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥406.3bn | 2022-04-01 → 2022-12-31 | Cons. | Net sales |
| Revenue | ¥494.8bn | 2021-04-01 → 2022-03-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥369.4bn | 2021-04-01 → 2021-12-31 | Cons. | Net sales |
| Operating income | ¥13.2bn | 2022-04-01 → 2022-12-31 | Cons. | Operating income |
| Operating income | ¥19.7bn | 2021-04-01 → 2021-12-31 | Cons. | Operating income |
| Ordinary income | ¥13.8bn | 2022-04-01 → 2022-12-31 | Cons. | Ordinary income |
| Ordinary income | ¥27.6bn | 2021-04-01 → 2022-03-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥20.6bn | 2021-04-01 → 2021-12-31 | Cons. | Ordinary income |
| Profit before tax | ¥14.7bn | 2022-04-01 → 2022-12-31 | Cons. | Income before income taxes |
| Profit before tax | ¥19.1bn | 2021-04-01 → 2021-12-31 | Cons. | Income before income taxes |
| Net income (owners) | ¥7.0bn | 2022-04-01 → 2022-12-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥13.5bn | 2021-04-01 → 2022-03-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥11.0bn | 2021-04-01 → 2021-12-31 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥8.1bn | 2022-04-01 → 2022-12-31 | Cons. | Profit loss |
| Net income | ¥12.2bn | 2021-04-01 → 2021-12-31 | Cons. | Profit loss |
| Total assets | ¥1.05T | at 2022-12-31 | Cons. | Assets |
| Total assets | ¥930.3bn | at 2022-03-31 | Cons. | Assets |
| Total assets | ¥902.8bn | at 2021-12-31 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥809.0bn | at 2022-12-31 | Cons. | Liabilities |
| Total liabilities | ¥730.5bn | at 2022-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥240.2bn | at 2022-12-31 | Cons. | Net assets |
| Net assets / equity | ¥199.9bn | at 2022-03-31 | Cons. | Net assets |
| Net assets / equity | ¥193.7bn | at 2021-12-31 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥102.7bn | at 2022-12-31 | Cons. | Cash and deposits |
| Cash and deposits | ¥95.3bn | at 2022-03-31 | Cons. | Cash and deposits |
| EPS (basic) | ¥42.69 | 2022-04-01 → 2022-12-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥4.35 | 2022-10-01 → 2022-12-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥82.5 | 2021-04-01 → 2022-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥67.68 | 2021-04-01 → 2021-12-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥22.9 | 2021-10-01 → 2021-12-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥37.82 | 2022-04-01 → 2022-12-31 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥77.42 | 2021-04-01 → 2022-03-31 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥64.77 | 2021-04-01 → 2021-12-31 | Cons. | Diluted earnings per share (5-year summary) |
| Equity ratio | 21.3% | at 2022-12-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 19.9% | at 2022-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 19.9% | at 2021-12-31 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 54
| Segment | Item | Period | Value |
|---|---|---|---|
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2022-04-01 → 2022-12-31 | ¥3.2bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2022-04-01 → 2022-12-31 | ¥530m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2022-04-01 → 2022-12-31 | ¥2.6bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2022-04-01 → 2022-12-31 | ¥166m |
| Reconciling Itemsreconciling | revenue | 2022-04-01 → 2022-12-31 | −¥28.6bn |
| Reconciling Itemsreconciling | revenue intersegment | 2022-04-01 → 2022-12-31 | −¥28.6bn |
| Reconciling Itemsreconciling | segment profit | 2022-04-01 → 2022-12-31 | −¥22.5bn |
| jpcrp040300-q3r_E02688-000Medical Treatment Relatedreportable segment | revenue | 2022-04-01 → 2022-12-31 | ¥318.8bn |
| jpcrp040300-q3r_E02688-000Medical Treatment Relatedreportable segment | revenue external | 2022-04-01 → 2022-12-31 | ¥314.2bn |
| jpcrp040300-q3r_E02688-000Medical Treatment Relatedreportable segment | revenue intersegment | 2022-04-01 → 2022-12-31 | ¥4.6bn |
| jpcrp040300-q3r_E02688-000Medical Treatment Relatedreportable segment | segment profit | 2022-04-01 → 2022-12-31 | ¥30.8bn |
| jpcrp040300-q3r_E02688-000Medicine Relatedreportable segment | revenue | 2022-04-01 → 2022-12-31 | ¥70.3bn |
| jpcrp040300-q3r_E02688-000Medicine Relatedreportable segment | revenue external | 2022-04-01 → 2022-12-31 | ¥53.6bn |
| jpcrp040300-q3r_E02688-000Medicine Relatedreportable segment | revenue intersegment | 2022-04-01 → 2022-12-31 | ¥16.8bn |
| jpcrp040300-q3r_E02688-000Medicine Relatedreportable segment | segment profit | 2022-04-01 → 2022-12-31 | ¥2.2bn |
| jpcrp040300-q3r_E02688-000Pharma Packagingreportable segment | revenue | 2022-04-01 → 2022-12-31 | ¥42.6bn |
| jpcrp040300-q3r_E02688-000Pharma Packagingreportable segment | revenue external | 2022-04-01 → 2022-12-31 | ¥38.0bn |
| jpcrp040300-q3r_E02688-000Pharma Packagingreportable segment | revenue intersegment | 2022-04-01 → 2022-12-31 | ¥4.6bn |
| jpcrp040300-q3r_E02688-000Pharma Packagingreportable segment | segment profit | 2022-04-01 → 2022-12-31 | ¥2.5bn |
| —segment total | revenue | 2022-04-01 → 2022-12-31 | ¥431.7bn |
| —segment total | revenue external | 2022-04-01 → 2022-12-31 | ¥405.8bn |
| —segment total | revenue intersegment | 2022-04-01 → 2022-12-31 | ¥25.9bn |
| —segment total | segment profit | 2022-04-01 → 2022-12-31 | ¥35.5bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2022-04-01 → 2022-12-31 | ¥434.9bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2022-04-01 → 2022-12-31 | ¥406.3bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2022-04-01 → 2022-12-31 | ¥28.6bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2022-04-01 → 2022-12-31 | ¥35.7bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2021-04-01 → 2021-12-31 | ¥1.9bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2021-04-01 → 2021-12-31 | ¥446m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2021-04-01 → 2021-12-31 | ¥1.5bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2021-04-01 → 2021-12-31 | ¥258m |
| Reconciling Itemsreconciling | revenue | 2021-04-01 → 2021-12-31 | −¥26.6bn |
| Reconciling Itemsreconciling | revenue intersegment | 2021-04-01 → 2021-12-31 | −¥26.6bn |
| Reconciling Itemsreconciling | segment profit | 2021-04-01 → 2021-12-31 | −¥20.2bn |
| jpcrp040300-q3r_E02688-000Medical Treatment Relatedreportable segment | revenue | 2021-04-01 → 2021-12-31 | ¥284.8bn |
| jpcrp040300-q3r_E02688-000Medical Treatment Relatedreportable segment | revenue external | 2021-04-01 → 2021-12-31 | ¥280.0bn |
| jpcrp040300-q3r_E02688-000Medical Treatment Relatedreportable segment | revenue intersegment | 2021-04-01 → 2021-12-31 | ¥4.8bn |
| jpcrp040300-q3r_E02688-000Medical Treatment Relatedreportable segment | segment profit | 2021-04-01 → 2021-12-31 | ¥31.0bn |
| jpcrp040300-q3r_E02688-000Medicine Relatedreportable segment | revenue | 2021-04-01 → 2021-12-31 | ¥70.1bn |
| jpcrp040300-q3r_E02688-000Medicine Relatedreportable segment | revenue external | 2021-04-01 → 2021-12-31 | ¥54.4bn |
| jpcrp040300-q3r_E02688-000Medicine Relatedreportable segment | revenue intersegment | 2021-04-01 → 2021-12-31 | ¥15.7bn |
| jpcrp040300-q3r_E02688-000Medicine Relatedreportable segment | segment profit | 2021-04-01 → 2021-12-31 | ¥6.1bn |
| jpcrp040300-q3r_E02688-000Pharma Packagingreportable segment | revenue | 2021-04-01 → 2021-12-31 | ¥39.1bn |
| jpcrp040300-q3r_E02688-000Pharma Packagingreportable segment | revenue external | 2021-04-01 → 2021-12-31 | ¥34.5bn |
| jpcrp040300-q3r_E02688-000Pharma Packagingreportable segment | revenue intersegment | 2021-04-01 → 2021-12-31 | ¥4.6bn |
| jpcrp040300-q3r_E02688-000Pharma Packagingreportable segment | segment profit | 2021-04-01 → 2021-12-31 | ¥2.5bn |
| —segment total | revenue | 2021-04-01 → 2021-12-31 | ¥394.1bn |
| —segment total | revenue external | 2021-04-01 → 2021-12-31 | ¥368.9bn |
| —segment total | revenue intersegment | 2021-04-01 → 2021-12-31 | ¥25.1bn |
| —segment total | segment profit | 2021-04-01 → 2021-12-31 | ¥39.6bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2021-04-01 → 2021-12-31 | ¥396.0bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2021-04-01 → 2021-12-31 | ¥369.4bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2021-04-01 → 2021-12-31 | ¥26.6bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2021-04-01 → 2021-12-31 | ¥39.9bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 449
| Item | Context | Value | Unit |
|---|---|---|---|
| Revenues from external customers | Prior1YTDDuration | 369356000000 | JPY |
| Transactions with other segments | Prior1YTDDuration_jpcrp040300-q3r_E02688-000MedicalTreatmentRelatedReportableSegmentsMember | 4819000000 | JPY |
| Transactions with other segments | Prior1YTDDuration_jpcrp040300-q3r_E02688-000MedicineRelatedReportableSegmentsMember | 15722000000 | JPY |
| Transactions with other segments | Prior1YTDDuration_jpcrp040300-q3r_E02688-000PharmaPackagingReportableSegmentMember | 4602000000 | JPY |
| Transactions with other segments | Prior1YTDDuration_ReportableSegmentsMember | 25145000000 | JPY |
| Transactions with other segments | Prior1YTDDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | 1451000000 | JPY |
| Transactions with other segments | Prior1YTDDuration_TotalOfReportableSegmentsAndOthersMember | 26596000000 | JPY |
| Transactions with other segments | Prior1YTDDuration_ReconcilingItemsMember | -26596000000 | JPY |
| Transactions with other segments | Prior1YTDDuration | － | JPY |
| Net sales | Prior1YTDDuration_jpcrp040300-q3r_E02688-000MedicalTreatmentRelatedReportableSegmentsMember | 284841000000 | JPY |
| Net sales | Prior1YTDDuration_jpcrp040300-q3r_E02688-000MedicineRelatedReportableSegmentsMember | 70073000000 | JPY |
| Net sales | Prior1YTDDuration_jpcrp040300-q3r_E02688-000PharmaPackagingReportableSegmentMember | 39139000000 | JPY |
| Net sales | Prior1YTDDuration_ReportableSegmentsMember | 394055000000 | JPY |
| Net sales | Prior1YTDDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | 1898000000 | JPY |
| Net sales | Prior1YTDDuration_TotalOfReportableSegmentsAndOthersMember | 395953000000 | JPY |
| Net sales | Prior1YTDDuration_ReconcilingItemsMember | -26596000000 | JPY |
| Net sales | Prior1YTDDuration | 369356000000 | JPY |
| Operating income | Prior1YTDDuration_jpcrp040300-q3r_E02688-000MedicalTreatmentRelatedReportableSegmentsMember | 30992000000 | JPY |
| Operating income | Prior1YTDDuration_jpcrp040300-q3r_E02688-000MedicineRelatedReportableSegmentsMember | 6121000000 | JPY |
| Operating income | Prior1YTDDuration_jpcrp040300-q3r_E02688-000PharmaPackagingReportableSegmentMember | 2525000000 | JPY |
| Operating income | Prior1YTDDuration_ReportableSegmentsMember | 39639000000 | JPY |
| Operating income | Prior1YTDDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | 258000000 | JPY |
| Operating income | Prior1YTDDuration_TotalOfReportableSegmentsAndOthersMember | 39898000000 | JPY |
| Operating income | Prior1YTDDuration_ReconcilingItemsMember | -20162000000 | JPY |
| Operating income | Prior1YTDDuration | 19735000000 | JPY |
| Revenues from external customers | CurrentYTDDuration_jpcrp040300-q3r_E02688-000MedicalTreatmentRelatedReportableSegmentsMember | 314226000000 | JPY |
| Revenues from external customers | CurrentYTDDuration_jpcrp040300-q3r_E02688-000MedicineRelatedReportableSegmentsMember | 53553000000 | JPY |
| Revenues from external customers | CurrentYTDDuration_jpcrp040300-q3r_E02688-000PharmaPackagingReportableSegmentMember | 37990000000 | JPY |
| Revenues from external customers | CurrentYTDDuration_ReportableSegmentsMember | 405770000000 | JPY |
| Revenues from external customers | CurrentYTDDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | 530000000 | JPY |
| Revenues from external customers | CurrentYTDDuration_TotalOfReportableSegmentsAndOthersMember | 406301000000 | JPY |
| Revenues from external customers | CurrentYTDDuration_ReconcilingItemsMember | － | JPY |
| Revenues from external customers | CurrentYTDDuration | 406301000000 | JPY |
| Transactions with other segments | CurrentYTDDuration_jpcrp040300-q3r_E02688-000MedicalTreatmentRelatedReportableSegmentsMember | 4597000000 | JPY |
| Transactions with other segments | CurrentYTDDuration_jpcrp040300-q3r_E02688-000MedicineRelatedReportableSegmentsMember | 16772000000 | JPY |
| Transactions with other segments | CurrentYTDDuration_jpcrp040300-q3r_E02688-000PharmaPackagingReportableSegmentMember | 4571000000 | JPY |
| Transactions with other segments | CurrentYTDDuration_ReportableSegmentsMember | 25941000000 | JPY |
| Transactions with other segments | CurrentYTDDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | 2621000000 | JPY |
| Transactions with other segments | CurrentYTDDuration_TotalOfReportableSegmentsAndOthersMember | 28563000000 | JPY |
| Transactions with other segments | CurrentYTDDuration_ReconcilingItemsMember | -28563000000 | JPY |
| Transactions with other segments | CurrentYTDDuration | － | JPY |
| Net sales | CurrentYTDDuration_jpcrp040300-q3r_E02688-000MedicalTreatmentRelatedReportableSegmentsMember | 318823000000 | JPY |
| Net sales | CurrentYTDDuration_jpcrp040300-q3r_E02688-000MedicineRelatedReportableSegmentsMember | 70326000000 | JPY |
| Net sales | CurrentYTDDuration_jpcrp040300-q3r_E02688-000PharmaPackagingReportableSegmentMember | 42561000000 | JPY |
| Net sales | CurrentYTDDuration_ReportableSegmentsMember | 431712000000 | JPY |
| Net sales | CurrentYTDDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | 3152000000 | JPY |
| Net sales | CurrentYTDDuration_TotalOfReportableSegmentsAndOthersMember | 434864000000 | JPY |
| Net sales | CurrentYTDDuration_ReconcilingItemsMember | -28563000000 | JPY |
| Net sales | CurrentYTDDuration | 406301000000 | JPY |
| Operating income | CurrentYTDDuration_jpcrp040300-q3r_E02688-000MedicalTreatmentRelatedReportableSegmentsMember | 30788000000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 12 of 12 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |